Many secreted signaling molecules are synthesized as precursors that undergo multiple maturation steps to generate their mature forms. The Saccharomyces cerevisiae mating pheromone a-factor is a C-terminally isoprenylated and carboxylmethylated dodecapeptide that is initially synthesized as a larger precursor containing 36 or 38 amino acids. We have previously shown that the maturation of a-factor occurs by an ordered biogenesis pathway involving 1) three C-terminal modification steps, 2) two N-terminal proteolytic processing events, and 3) a nonclassical export mechanism mediated by the ATP-binding-cassette (ABC) transporter Ste6p. In the present study, we demonstrate that an unexpected and abundant a-factor-related peptide (AFRP) exists in the culture fluid of MATa cells and that its biogenesis is integrally related to that of mature a-factor itself. We show by purification followed by mass spectrometry that AFRP corresponds to the C-terminal 7 amino acids (VFWDPAC) of mature a-factor (YIIKGVFWDPAC), including both the farnesyl-and carboxylmethylcysteine modifications. The formation and export of AFRP displays three striking features. First, we show that AFRP is produced intracellularly and that mutants (ste24 and axll) that cannot produce mature a-factor due to an N-terminal processing defect are nevertheless normal for AFRP production. Thus, AFRP is not derived from mature a-factor but, instead, from the P1 form of the a-factor precursor. Second, fusion constructs with foreign amino acids substituted for authentic a-factor residues still yield AFRP-sized molecules; however, the composition of these corresponds to the altered residues instead of to AFRP residues. Thus, AFRP may be generated by a sequence-independent but length-specific proteolytic activity. Third, a-factor and AFRP use distinct cellular machinery for their secretion. Whereas a-factor export is Ste6p-dependent, AFRP is secreted normally even in a ste6 deletion mutant. Thus, AFRP may exit the cell by another ATP-binding-cassette transporter, a different type of transporter altogether, or possibly by diffusion. Taken together, these studies indicate that the biogenesis of AFRP involves novel mechanisms and machinery, distinct from those used to generate mature a-factor. Because AFRP neither stimulates nor inhibits mating or a-factor halo activity, its function remains an intriguing question.
INTRODUCTION
proteolytic processing events during their biogenesis (Resnick and Zasloff, 1992 ). The precise characterization of the site of these processing reactions within the maturing molecule is critical for providing insight into the biochemical nature of these reactions and ultimately for identifying the cellular components that mediate them.
The yeast mating pheromone a-factor is an isoprenylated and carboxylmethylated oligopeptide signaling molecule, initially synthesized as a larger precursor. The biogenesis of the a-factor precursor to yield mature bioactive a-factor is a multistep process that involves C-terminal modification, Nterminal processing, and secretion via a nonclassical export mechanism (Chen et al., 1997 ; see also Figure  13 for a summary of the a-factor biogenesis pathway). The C-terminal modification of the a-factor precursor is directed by its C-terminal CAAX motif (C is cysteine, A is an aliphatic residue, and X is one of many residues), which is present in all proteins that are destined for isoprenylation (Zhang and Casey, 1996) . The C-terminal modification of the a-factor precursor, as well as of Ras and other CAAX proteins, has three ordered steps: covalent addition of a farnesyl isoprenoid by the Ramlp/Ram2p prenyltransferase, proteolytic removal of the three terminal AAX residues (which correspond to VIA for a-factor), by Rcelp and possibly Afcl/Ste24p and methylation of the newly exposed cysteine carboxyl group by the Stel4p methyltransferase (see Figure  13 ; He et al., 1991; Hrycyna et al., 1991; Ashby et al., 1992; Hrycyna and Clarke, 1992; Boyartchuk et al., 1997) . The N-terminal proteolytic maturation of afactor, which takes place after the completion of C-terminal modification, involves two sequential proteolytic cleavage events. The first cleavage occurs within the N-terminal extension (between T7 and A8 of the a-factor precursor); the second cleavage occurs at the junction of the N-terminal extension and mature a-factor (between N21 and Y22) to generate mature bioactive a-factor (Chen et al., 1997 ; see also Figure 13 ). These cleavages are mediated by the zinc metalloproteases Ste24p and Axllp, respectively (Adames et al., 1995; Fujimura-Kamada et al, 1997) . Once formed, mature a-factor is exported from the cell. An intriguing feature of the biogenesis of a-factor is its nonclassical export mechanism. Unlike most secreted molecules that are matured and exported through the classical secretory pathway (Schekman, 1985; Pryer et al., 1992) , the export of a-factor is mediated by Ste6p, which belongs to the ATP binding cassette (ABC) superfamily of transporters (Kuchler et al., 1989; Michaelis, 1993) .
Our understanding of a-factor biogenesis, described above, is based upon our characterization of the a-factor biosynthetic intermediates P0, P1, P2, and M (see Figure 13 ). These intermediates can be detected by metabolic labeling, immunoprecipitation, and SDS-PAGE analysis of a-factor, expressed from either of two functionally redundant genes, MFA1 or MFA2 (Brake et al., 1985; Michaelis and Herskowitz, 1988) . We have established the identity of these species by determining their N-terminal amino acid composition and C-terminal modification status. P0 corresponds to the unmodified a-factor precursor, P1 corresponds to the fully C-terminally modified precursor, P2 corresponds to the first N-terminally cleaved species, and M corresponds to mature a-factor (Chen et al., 1997) .
During our initial analyses of a-factor biogenesis, we occasionally observed a novel a-factor-related peptide (hereafter referred to by the acronym AFRP) whose origin was puzzling. The AFRP species could often, but not always, be observed in intracellular immunoprecipitates, depending upon the preparation of a-factor antiserum that we used (see for instance Sapperstein et al., 1994; Chen et al., 1997) . On the other hand, AFRP was always apparent along with mature a-factor upon examination of the extracellular culture fluid, when this fraction was examined in the absence of immunoprecipitation. These findings suggested that AFRP is recognized by a-factor antiserum, but very poorly.
AFRP is the focus of the present study. AFRP is abundant; it is present at approximately the same level as mature a-factor itself. We demonstrate that AFRP, like a-factor, is derived from the MFA1 and MFA2 genes and that AFRP is an "alternative cleavage product" generated in parallel with mature a-factor. By plasma desorption mass spectrometry (PDMS) of high-pressure liquid chromatography (HPLC)-purified AFRP, we show that AFRP corresponds to the C-terminal seven residues of mature a-factor, including its farnesyl and carboxylmethyl -modifications. AFRP also contains an additional 16 mass units, most likely due to the addition of an oxygen on the side chain of one of its residues. We find neither a-factorlike activity nor inhibitory activity associated with the HPLC fraction containing AFRP, so that even though AFRP is abundant its biological role is not clear. In addition to determining its composition, we have examined the biogenesis of AFRP. These studies reveal three striking aspects of the processing and export of AFRP. First, AFRP is generated from a precursor form of a-factor, P1, in parallel with, and not from, mature a-factor. Second, our data suggest that AFRP could be generated by a sequence-independent but length-measuring proteolytic activity that may use prenylcysteine as its landmark and cleave a relatively fixed distance from it, regardless of the amino acids located at that site. Third, unlike mature a-factor, the export of AFRP is STE6 independent, suggesting that AFRP may use a novel transporter for its exit from the cell. Thus, these results suggest the existence of novel proteolytic processing and export components specifically dedicated Adames et al. (1995) to the production of AFRP and distinct from those components known to mediate the biogenesis of a-factor.
MATERIALS AND METHODS Yeast Strains and Media
Yeast strains used in this study are listed in Table 1 . Complete medium (YEPD), synthetic drop-out medium (SC-URA and SC-TRP), and SD minimal medium were prepared as described previously (Michaelis and Herskowitz, 1988) , except that drop-out medium is lacking L-methionine and L-cysteine for the metabolic labeling experiments with [35Slcysteine. Where necessary, SD medium was supplemented with L-histidine (20 ,g/ml), L-tryptophan (20 jig/ml), or L-leucine (30 ,ug/ml) and uracil (20 ,ug/ml). Strains were grown at 30°C, unless otherwise specified.
Plasmids and Manipulations of DNA
Plasmids used in this study are listed in Table 2 . Mutant allele designations are also described in Table 2 . Constructions were carried out as follows: The mutants mfal::DP(21) and mfal::DP(32) contain an insertion of two codons, DP, encoding a BamHI recognition sequence just preceding codons 21 and 32 of MFA1, respectively. They were generated via site-directed mutagenesis (Kunkel et al., 1987) using the oligonucleotide sequences oSM23 (5'-TT-GATAATATAGGGATCCTTGTCCTTCTTT-3') and oSM18 (5'-GC-AATAACACATGGATCCGCTGGGTCCCAG-3'), respectively, with the mutagenic residues underlined. The MFAl template was pSM233 and the resultant mutant plasmids were designated pSM309 and pSM255. To construct a mutant in which the portion of MFAl corresponding to the mature a-factor coding sequence was deleted, a 0.9-kb BamHI-XbaI fragment was deleted from pSM309 and replaced with the analogous BamHI-XbaI fragment from pSM255. By this reconstitution, resulting in pSM291, the mature a-factor coding sequence is precisely deleted (A21-32) and is replaced by the DP codon pair. We generated versions of MFA1 in which one of two epitope tags (El or hemagglutinin [HA] ) was inserted into, or substituted for, the mature coding sequence of a-factor. To generate a BamHI-ended El epitope tag sequence, BamHI sites were introduced by oligonucleotide mutagenesis into a C-terminal portion of the coronavirus El glycoprotein coding sequence, by using plasmid p57-6 (Machamer and Rose, 1987) as the template. The amino acid sequence of the BamHI-ended El epitope tag is DPMFVYAKQSVDTGELESVAT-GGSSLYTMDP. A synthetic peptide corresponding to this sequence (minus the flanking DP codons) had been previously used to generate polyclonal antiserum (Machamer and Rose, 1987) . The resulting BamHI-ended El tag was subcloned into pRS316 (Sikorski and Hieter, 1989 ) yielding pSM224, which was used as the source of the El tag in the subsequent clonings. To generate a version of MFAl with the El epitope inserted within mature a-factor, the El-containing BamHI fragment from pSM224 was subcloned into pSM255 at the BamHI site preceding codon 32, yielding pSM241. To generate a version of MFA1 in which the mature a-factor amino acids are replaced by the El epitope tag, the BamHI fragment from pSM224 was subcloned into pSM291 to yield pSM319.
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preparation of intracellular and extracellular fractions, and immunoprecipitation with a-factor rabbit polyclonal antiserum 9-137 or 9-497 were carried out as described (Chen et al., 1997) . These antisera were raised against the unmodified a-factor 12-mer peptide in separate rabbits (Chen et al., 1997 a-Factor Activity Assay
The a-factor activity was measured using the semiquantitative ahalo dilution assay (Berkower and Michaelis, 1993; Nijbroek and Michaelis, 1997 
HPLC Purification of a-Factor and AFRP
The procedure used to separate a-factor and AFRP is modified from methods previously used to purify a-factor (Strazdis and MacKay, 1982; Anderegg et al., 1988 A sample (5 ,ul) of each fraction (80 total) was diluted into 5 ,ul of YEPD-BSA medium, and 2 ,ul of each diluted fraction was screened for a-halo activity. The fractions showing a-halo activity were further diluted in 1:2 increments to quantify a-factor activity in each fraction.
To detect the fractions containing a-factor and AFRP, aliquots (60 pl) of each fraction were dried in a speed-vacuum concentrator, the dried material was resuspended in 5 pl of 1 x Laemmli sample buffer, and samples were analyzed by SDS-PAGE in 16% gels.
Plasma Desorption Mass Spectrometry
One-tenth of each HPLC fraction, containing either a-factor or AFRP, was dried in the speed-vacuum concentrator and redissolved in 10 ,ul of 50% methanol. The sample solution was then deposited Molecular Biology of the Cell on nitrocellulose-coated Mylar-backed aluminum foil (Applied Biosystems, Foster City, CA). After the sample solution was absorbed by the nitrocellulose (approximately 5 min), the sample foil was spin dried, followed by a microspin washing with 10 ,ul of 0.1% TFA. The plasma desorption mass spectra were recorded on a BIO-ION Nordic (Uppsala, Sweden) BIN-10K plasma desorption time-of-flight mass spectrometer, equipped with a 10-iCi 2Cf98 (Californium-252) ionization source. Spectra were collected by a PDP 11-73-based BIO-ION data system. Positive ion spectra were recorded with an accelerating voltage of +20 kV to present number of primary events (2 to 9 million) depending on the quality of each individual spectrum. H+ and Na+ (or NO') ions were used for mass calibration. The margin of error in these measurements is 0.1-0.2%, which is 1-2 Da per 1000.
RESULTS
Identification of a Novel a-Factor Related Peptide (AFRP) We previously characterized a-factor biosynthetic intermediates by metabolic labeling, immunoprecipitation, and SDS-PAGE analysis (Chen et al., 1997) ; in those studies we detected a novel a-factor species that was present in the nonimmunoprecipitated extracellular fraction. This species was also detectable occasionally, only under certain conditions, in immunoprecipitated samples from both the intracellular and extracellular fractions. In the present study, we pursued the identification and characterization of this a-factor-related species. To visualize this novel species, strains expressing the a-factor gene MFAl, or lacking a-factor altogether (mfalA mfa2A), were labeled with [35S]cysteine under steady-state conditions and separated into intracellular and extracellular fractions. Immunoprecipitation using a-factor antiserum 9-137, followed by SDS-PAGE reveals the expected intermediates ( Figure 1 , lanes 1 and 2), which are the partially processed precursor species (P1 and P2) and the fully processed mature (M) a-factor (Chen et al., 1997) . However, when total proteins from the culture medium were examined without immunoprecipitation, along with a-factor itself, an additional [35S]cysteine-labeled species was observed that had a slightly faster electrophoretic mobility than that of mature afactor ( Figure 1 , lane 3). It should be noted that a faint band corresponding to this species is also detectable in the intracellular immunoprecipitate (lane 1). Because this molecule was only found in cells carrying the MFA1 gene but not in cells deleted for the a-factor genes ( Figure 1 , compare lanes 3 and 6), it seemed highly likely that this rapidly migrating species is derived from the MFA1 gene. We have designated this species AFRP, for a-factor-related peptide (AFRP). Because AFRP is metabolically labeled by [35S]cysteine and because there is only a single cysteine residue at the C terminus of the MFA1 gene, we hypothesized that AFRP must be derived from the C-terminal portion of the a-factor gene. and 4) and extracellular (E; lanes 2 and 5) fractions were immunoprecipitated with a-factor antiserum 9-137 and analyzed by SDS-PAGE on 16% gels. The extracellular fraction was also examined without immunoprecipitation to assess the total protein profile (T; lanes 3 and 6). The strains labeled are SM1229 (Amfal, Amfa2) containing the plasmid pSM464 (CEN MFA1) (WT) or no plasmid (NULL). The a-factor species P1, P2, and M and AFRP are indicated on the left; molecular weight markers are shown on the right.
AFRP was also observed when the MFAl gene was expressed from the chromosome, instead of from a plasmid, indicating that appearance of AFRP does not result from overproduction of the a-factor gene. Likewise strains expressing solely MFA2 also generate AFRP, demonstrating that it can be generated from either of the a-factor precursors (our unpublished results). Moreover, AFRP was present in the culture medium of several Saccharomyces cerevisiae strains with distinctively different genetic lineages from our strain background; thus production of AFRP is not a strainspecific phenomenon (our unpublished results).
To analyze AFRP biosynthesis kinetically and to compare the rate of its formation and export with that of mature a-factor, we carried out a pulse-chase experiment in which immunoprecipitated and nonimmunoprecipitated samples were analyzed ( Figure 2 ). AFRP is evident both in the intracellular immunoprecipitated and extracellular nonimmunoprecipitated fractions, but not in the extracellular immunoprecipitated fraction, as was also the case in Figure 1 . The reason for the low immunoreactivity seen for AFRP in the extracellular immunoprecipitated sample is not clear but may in part be due to a difference in the composition between intracellular and extracellular AFRP that could influence antibody recognition, as discussed below. Overall, the kinetics of formation and export of AFRP are strikingly similar to those of mature a-factor. The formation and export of both species are rapid, with processing completed within 5 min Vol. 8, July 1997 Figure 2. Kinetic analysis of AFRP biosynthesis. Cells were pulse labeled with [35S]cysteine for 2 min and chased for the indicated times. Immunoprecipitated (IP) intracellular and extracellular fractions and the nonimmunoprecipitated (NON-IP) extracellular fractions were analyzed by SDS-PAGE on 16% gels. The afactor antiserum used for immunoprecipitation was 9-497. The a-factor species are indicated. The strain labeled is SM1058 containing the plasmid pSM219 (2,u MFA1). The similarity in the kinetic parameters, and in the amounts of AFRP and a-factor that are generated and exported, suggests that their formation and exit from the cell occur concurrently. analyzed for a-factor and AFRP production ( Figure 3 ).
Both species, mature a-factor and AFRP, were produced from the strain expressing WT MFAl (lanes 1 and 7). In contrast, neither a-factor nor AFRP were found in the mfal-AI35, mfal-AVIA(34-36), raml, or ram2 mutants, all of which are blocked for the farnesylation of the a-factor precursor (Powers et al., 1986; He et al., 1991; Sapperstein et al., 1994; Chen et al., 1997) . Rather, only the unmodified a-factor precursor, PO, was apparent in these strains ( Figure 3 , lanes 2-5). Thus, farnesylation of the CAAX cysteine residue is critical for the production of AFRP, as well as for the production of mature a-factor. Both mature a-factor and AFRP are generated intracellularly in a stel4 mutant in which the C-terminal methylation of a-factor is blocked ( Figure 3 , lane 6; Sapperstein et al., 1994) . Interestingly, however, the unmethylated a-factor and AFRP formed in the stel4 mutant exhibit a distinctive difference from one another. Although a-factor is absent in the culture medium of a stel4 mutant, as has been seen previously (Sapperstein et al., 1994) , AFRP is present (Figure 3 , lane 6). Thus, unmethylated AFRP can apparently be exported, whereas unmethylated a-factor cannot be (Sapperstein et al., 1994 Adames et al., 1995) . In these mutants the amount of mature a-factor (M) that is generated is either greatly diminished or abolished, respectively. As shown in Figure 4 , AFRP is present at normal levels in both mutants, even though mature a-factor is highly reduced or absent altogether ( Figure  4 , compare lanes 2 and 3 with 1 and 4). In a separate experiment, we analyzed a cis-acting mutant mfal-ANY(21-22), in which the cleavage that generates ma- I-z T-(n 3;: ture a-factor is blocked; again, we found that AFRP production is unaffected (our unpublished results). The observation that AFRP is present in normal amounts in a ste24A mutant that is blocked for conversion of P1 --P2 suggests that AFRP is generated directly from the a-factor precursor species P1, which is C-terminally modified and has an intact N terminus.
AFRP Is Derived from the C-Terminal Portion of MFA1 Gene To further examine the hypothesis that AFRP is directly derived from the C-terminal portion of MFAl, an a-factor deletion strain carrying a 2,u MFA1 plasmid was metabolically labeled with either [3Hllysine or [35S] cysteine, and their labeling pattern was compared. Lysine is present near the N terminus of mature a-factor, at position 4 of 12 (see Figure 13 ). As expected, when intracellular immunoprecipitated a-factor was analyzed, both mature a-factor and AFRP Purification of a-Factor and AFRP from Culture Medium To determine the structure of AFRP, we purified afactor and AFRP from yeast culture fluid. An a-factor deletion strain carrying a high-copy-number MFAl plasmid was used because it produces 10-fold more a-factor and AFRP than strains bearing only the chromosomal a-factor genes (Chen et al., 1997) . The purification steps used in this study are a modification of previously published procedures (Strazdis and MacKay, 1982; Betz et al., 1987) , designed for the concentration of mature a-factor. Clarified culture medium was exposed to Amberlite XAD-2 polystyrene beads to adsorb a-factor and AFRP. Adsorbed material was eluted in 100% n-propanol. The eluted material was subjected to C18 reverse-phase HPLC chromatography using a stepped linear MeOH gradient (see MATERIALS AND METH-ODS for details). Each fraction was monitored by the a-factor halo activity assay ( Figure 6A ) and by SDS-PAGE ( Figure 6B ). For the latter purpose, a small amount of [35Slcysteine-labeled radioactive tracer was added to the Amberlite bead eluate.
The XAD-2 bead adsorption yields approximately 50% of the original activity, as judged by the a-factor activity assay. Upon HPLC fractionation, a-factor activity was predominantly found in fraction 62 ( Figure  6A in fraction 62 ( Figure 6B ) correlating with the a-factor activity assay. Labeled AFRP was detected mainly in fractions 54 and 55, although some of AFRP-sized species were found in fractions 58 and 59 (and possibly fraction 64, although the migration of this species is not precisely the same as for AFRP; Figure 6B ). Little or no a-factor activity was found in any of the fractions containing AFRP. We also tested a-halo inhibitory activity in these fractions by adding AFRP to a-factor and carrying out a-factor halo dilution assays; however, no inhibitory activity was detected (our unpublished observations). Overall, a 30-fold purification of a-factor and AFRP was achieved by this two-step preparation, with the yield of a-factor representing 10-20% of the original activity in the culture medium.
(At least part of the loss during purification can be attributed to the very "sticky" nature of a-factor and AFRP, which results in their adherence to the walls of glass and polypropylene vessels.) The material obtained by the above procedure is sufficiently pure for subsequent PDMS analysis (below). The experiments discussed in the sections above indicate that AFRP is derived from the C-terminal portion of the a-factor precursor. To determine the precise composition of AFRP, HPLC fractions containing AFRP and a-factor were analyzed by PDMS (Macfarlane, 1981 ). a-Factor and AFRP from several indepen- Figure 7 (facing page). PDMS analysis of HPLC fractions containing a-factor or AFRP. Results of the PDMS analysis of HPLC-purified a-factor (fraction 62) and AFRP (fraction 54) from one purification (purification 1; Figure 6 ) are shown in A. The ordinate corresponds to intensity and the abscissa to the mass-to-charge ratio (m/z). In general, the observed peak corresponds to the mass of the species plus the mass of a proton [M+H+] . In the a-factor fraction (left), there is a major molecular ion of m/z 1630, which correlates with the predicted mass of mature a-factor (1629 Da), and a minor molecular ion of m/z 1425. The difference between these two ions is 205 Da, which corresponds to the mass of a farnesyl group. In the AFRP fraction (right), a major molecular ion of 1072 is apparent. (B) Results of PDMS analysis of a-factor and AFRP from a separate purification (purification 2). Similar molecular ions were detected as those described in A, except that an additional molecular ion (867) AFRP dent HPLC preparations were examined; the spectra from two of these are shown ( Figure 7, A and B) . The position of the peaks along the horizontal axis represents their mass-to-charge ratio (m/z), and the mass of each species is equivalent to its molecular weight plus a proton (+ 1). In one preparation, the PDMS spectrum of the a-factor fraction contains a major protonated molecular ion peak with a mass-to-charge ratio (m/z) of 1630 and a minor peak of m/z 1425 ( Figure 7A, left) . In another preparation, the same a-factor ions (a major peak of 1630 and a minor peak of 1425 [ Figure 7B , left]) were detected, although the latter spectrum exhibited a spread of species clustered around the peaks. The molecular weight of a-factor determined previously is 1629 Da (Anderegg et al., 1988 Figure  7A , right) and a pair of ions of m/z 1072 and 867 from the other ( Figure 7B , right). As indicated in Figure 7C , the peak of 1072 Da corresponds to the seven Cterminal amino acids of a-factor including the farnesyl and methyl groups, plus an extra 16 Da. This structure of AFRP indicates that it must be generated by a proteolytic cleavage between residues G26 and V27 of the MFAI gene. In the AFRP fraction exhibiting two ions ( Figure 7B, right) , the difference between the major and minor peaks 1072 and 867, respectively, is 205 Da, correlating with the loss of a farnesyl group. For the AFRP and corresponding a-factor fractions derived from preparation 2 ( Figure 7B ), there are actually multiple AFRP species clustering around the major peak. The additional species that contribute to the width of this peak are in secondary peaks, 16 mass units apart, suggesting significant oxidation of this sample during purification. The lack of a defarnesylated ion in the first AFRP preparation ( Figure 7A ) may reflect the low abundance of the material that was analyzed (notice the signal-to-noise ratio is much lower than for the other spectra). This low abundance may be due to inefficient adsorption of AFRP to the nitrocellulose foil used for PDMS. We have observed that AFRP does not adhere to nitrocellulose of certain lot numbers. In contrast, a-factor does not exhibit this lot-specific variability in adherence to nitrocellulose.
Our hypothesis is that the extra 16 Da present in AFRP represents oxidation of AFRP, which is consistent with the previous observation that a-factor itself may become significantly oxidized during purification (Betz et al., 1987) . However, whereas the authors of the previous study suggested that oxidation might occur on the farnesyl group, we found that the defarnesylated ion for a-factor (1425) and for AFRP (867) still bears the extra mass of 16 Da. This result indicates that oxidation does not occur on the farnesyl group, but most likely occurs within the peptide portion of AFRP. It is notable that although we detect both nonoxidized and oxidized a-factor ions, we have detected solely the oxidized form of AFRP.
PDMS Analysis of a-Factor and AFRP Produced by Two mfal Mutants
To further confirm the identity of AFRP and the cleavage site used to generate it, we sought to analyze a-factor and AFRP molecules derived from two mfal mutants, A32S and I23M, respectively. According to the proposed structure ( Figure 7C ), the AFRP derived from MFAI is generated by a cleavage between G26 and V27. Therefore, the mfal-A32S mutation should alter the mass of both a-factor and AFRP, whereas the mfal-123M mutation should alter the mass of a-factor but not of AFRP. Accordingly, we purified the a-factor and AFRP molecules produced by cells that carry plasmids bearing three different versions of MFA1 (WT, A32S, or 123M). When a-factor fractions were subjected to PDMS, we detected major ions of m/z 1647 from the A32S mutant ( Figure 8C ) and m/z 1649 from the 123M mutant ( Figure 8B ), as compared with m/z 1630 for WT a-factor ( Figure 8A ). These observed ions precisely correlate with the mass shift predicted to result from the A32S and 123M mutations. The characteristic minor ions, corresponding to defarnesylated species, are also apparent in each case.
For AFRP fractions subjected to PDMS, the major ion detected from the A32S mutant has a m/z of 1088 as compared with WT AFRP, whose m/z is 1072 (Figure 8, C versus A) . The difference corresponds to the replacement of alanine with serine in the mutant AFRP species. In contrast, the major ion detected from the 123M mutant is 1072 ( Figure 8B ), which is identical to WT AFRP. Therefore, the 123M mutation affects only a-factor but not AFRP and, thus, must lie outside of the region contained in AFRP. In summary, the PDMS analysis of a-factor and AFRP molecules derived from the mfal-A32S and mfal-I23M mutants provides compelling evidence that AFRP is generated from the C-terminal portion of the MFAl precursor; these findings are consistent with the conclusion that AFRP results from a cleavage between the residues G26 and V27.
It should be noted that ions corresponding to the defarnesylated forms of a-factor and AFRP were apparent in each case in Figure 8 and The major export route used by most secreted proteins in the cell is the classical secretory pathway (Schekman, 1985; Pryer et al., 1992) . To examine whether the secretion of AFRP relies on this pathway, we examined the appearance of AFRP in the culture fluid in a set of temperature-sensitive sec mutants, secl, sec 7, and secl8, that block the secretory pathway at discrete steps (Novick et al., 1981 Figure 10A ). The major AFRP-containing fraction (fraction 55) was subjected to PDMS ( Figure 10B ). The positive ions observed were m/z 1072 and m/z 867, which are the same as those detected from a WT strain (Figure 7) . Thus, the AFRP species secreted from a ste6 mutant has the same structure as that of AFRP from a WT strain. The presence of a normal amount of AFRP in the culture fluid of a ste6 mutant strain in which a-factor is entirely absent makes it unlikely that AFRP is derived from a-factor extracellularly, even in a WT strain.
Identification of AFRP-sized Molecules from Fusion Proteins
To analyze the specificity of the proteolytic events that generate AFRP we have constructed three epitopetagged a-factor fusion proteins, designated fusion 1, 2, and 3 [mfal::E1(32), mfal::HA(32), and mfal-A(21-32):: E1(32), respectively ( Figure 11A) ]. In these fusions, foreign amino acids are either added within (fusions 1 and 2) or substituted for (fusion 3) the mature region of MFAI. Strains expressing WT MFA1 or the fusion proteins were metabolically labeled and extracellular extracts were examined by SDS-PAGE for the secretion of species derived from the fusion proteins. Although an a-factor-sized peptide is not apparent for the fusions (Figure 1lB Because there is only one cysteine residue, located near the very C terminus of these fusion constructs, and because the AFRP-sized molecules can be labeled with
[35S]cysteine, the AFRP-sized species must derive from the C-terminal portion of the fusion proteins. If this hypothesis is correct, then the AFRP-sized peptides should have a very different amino acid sequence than authentic AFRP, sharing only its C-terminal famesylmethylcysteine. Consequently, the proteolytic cleavage event that generates these species must occur within the El or HA epitopes to generate AFRP-sized molecules. This implies the existence of a protease(s) that is able to cleave peptide bonds regardless of the peptide sequence. One difference between the cells expressing the WT MFA1 gene versus the fusion genes is that peptides migrating faster than WT AFRP were absent for WT, but present, in addition to the AFRP-sized peptides, for the fusion strains (Figure liB, lanes 3-5) . The identity of these species is addressed in the next section.
Purification and PDMS Analysis of the AFRP-sized Molecules Derived from Two Fusion Proteins
To determine the structure of the AFRP-sized molecules, fusion AFRPs from the culture fluid of an a-factor deletion strain carrying either fusion 1 [mfal::El(32)] or fusion 2 [mfal::HA(32)] were HPLCpurified as described above, using the appropriate
[35S]cysteine-labeled tracer. The fractions containing AFRP-sized species from the fusions were detected by SDS-PAGE analysis (Chen, 1993) . The major AFRP fraction (fraction 55) from fusion 1 [mfal::El(32)I was subjected to PDMS. As shown in Figure 12A , a group of peptides with m/z values of 949, 786, 685, 538, and 423 were observed, respectively ( Figure 12A ). If these are protonated species, then the molecular weights correlate with those calculated for a series of C-terminally farnesylated and methylated fusion peptides, ranging from 6 to 2 amino acids long. For fusion 2 [mfal::HA(32)], PDMS analysis of the major AFRPcontaining HPLC fraction (fraction 60) revealed a group of peptides with m/z values of 1199, 1084, 1000, 903, 624, and 569 ( Figure 12B ). These calculated molecular weights are consistent with those predicted for a series of C-terminally farnesylated and methylated fusion peptides ranging from 9 to 3 amino acids long.
(It should be noted that the lack of 15 mass units [-151 for several species in Figure 12 is likely to correspond to loss of the methyl group, and the addition of 16 mass units [+16] is presumed to correspond to oxidation.) Presumably, the collection of AFRP-sized species made by fusions 1 and 2 reflect hetergeneity during the cleavage event that yields them. Alternatively, these smaller species may be generated by proteases in the culture fluid. The reason for the high level of fragmentation observed for the fusion-derived AFRP species, in contrast to the low level of fragmentation for a-factor-derived AFRP is not clear. From our findings, we can determine the presumed sites of cleavage used to generate the fusion-derived AFRPs. The sites from which the largest peptides are generated are between residues Leu and Tyr (fusion 1) and Tyr and Asp (fusion 2), in contrast to Gly and Val for true AFRP. Although the AFRP species derived from WT MFA1 and fusions 1 and 2 share a prenlyated methylated cysteine residue preceded by Asp-Pro, the remaining residues are not shared. Thus, the structural determination of these fusion AFRPs demonstrates that C-terminally famesylated and methylated peptides can be generated and exported regardless of their peptide sequence, implying the possible existence of both novel processing and export mechanisms, distinct from those involved in the biogenesis of a-factor per se. Figure 12 . Purification and structural determination of AFRP-sized molecules from mfal::El and mfal::HA fusions. AFRP-sized molecules from strains expressing the mfal::El (A) and mfal::HA (B) fusions were purified from the culture fluid by adsorption to the XAD-2 resin and reverse-phase HPLC. HPLC fractions 1-80 were analyzed by SDS-PAGE and autoradiography. The fractions containing fusion AFRPs were detected by following the corresponding radiolabeled tracers. The peak fraction containing fusion AFRPs (fractions 55 and 60, respectively) were analyzed by PDMS. Several molecular ions are apparent. The deduced structures of the fusion AFRPs are shown below the spectrum; the sites of cleavage generating these species are indicated by arrows (above). Strains are SM1458 containing plasmids pSM241 (A) and pSM357 (B).
DISCUSSION
Comparison of the Biogenesis Pathway of a-Factor versus AFRP In this study, we have identified and characterized a novel peptide secreted by S. cerevisiae. The production of this peptide, which we have designated AFRP (for a-factor-related peptide), is integrally related to the production of the a-factor mating pheromone. Purification and mass spectrometry of AFRP has revealed that it contains the same C-terminal seven amino acids as mature a-factor, including the farnesyl and carboxylmethyl modifications of cysteine (plus 16 additional mass units that are likely to result from the oxidation of an amino acid side chain). The presence of this alternative form of a-factor can explain, in part, one unexpected feature of a-factor biogenesis, namely, its apparent inefficiency (Chen et al., 1997) . We now know that a portion of the total amount of a-factor precursor that is synthesized by the cell is converted to AFRP instead of mature a-factor, thus accounting for some of the "missing" a-factor. An important goal of the present study was to characterize the formation and export of AFRP. Figure 13 , the a-factor P1 precursor is subject to "alternative processing events" mediated by either Ste24p and Axllp (left) or by the AFRP protease (right), leading to the formation of either mature a-factor or AFRP, respectively. Second, the AFRP protease may operate by a sequence-independent but length-specific mechanism, possibly using prenylVol. 8, July 1997
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A-cysteine as a landmark from which to measure (see also below). This possibility is based upon the unexpected appearance of AFRP-sized molecules in the culture fluid of cells expressing fusion proteins containing foreign residues in place of authentic a-factor sequences. Third, and most strikingly, a-factor and AFRP appear to use different transporters to exit the cell: whereas the export of mature a-factor fails to occur in a ste6A mutant, the export of AFRP is unaffected. Furthermore, the carboxylmethyl group of a-factor, which is thought to be a critical recognition determinant for the Ste6p transporter (Sapperstein et al., 1994) , does not appear to be a critical determinant for AFRP secretion. This conclusion is based on our finding that although the export of a-factor is blocked in a stel4 mutant, which is defective in carrying out carboxylmethylation, the export of AFRP is unaffected. This result provides further evidence that a-factor and AFRP use distinct export mechanisms. (Gottesman and Pastan, 1993) . Likewise, the human TAP1 /TAP2 pump can transport peptides with completely different amino acid sequences across the endoplasmic reticulum membrane for antigen presentation (Parham, 1992) . Thus, given that the fusion-derived AFRP-sized molecules studied herein all appeared to be export substrates, even though they contain sequences distinctly different from one another and from authentic AFRP, an ABC superfamily member is a particularly compelling candidate for an AFRP transporter. We note that although our data does not rule out the possibility that AFRP and the AFRP-sized molecules derived from the fusion constructs could use distinct transporters, the possiblity of multiple transporters for these species seems unnecessarily complex. Recently, we carried out a homology search of the completed genome sequence of S. cerevisiae to identify all potential ABC proteins (Michaelis and Berkower, 1995; Taglicht and Michaelis, 1997) . We identified 30 ABC open reading frames, of which 22 (including Ste6p) are predicted to contain multiple membrane spans and are thus likely to function as true ABC transporters. Any of these could potentially function as an AFRP transporter, which can be tested by examining AFRP export in strains deleted for these genes or in strains overexpressing them.
It is also possible that a non-ABC type of transporter could be responsible for AFRP export. We have tested one such candidate, the nonclassical exporter Nce2p, which is a multiple membrane spanning protein that has been shown to mediate the transport, in yeast, of galectin, a mammalian nonclassical export substrate (Cleves et al., 1996) . Because AFRP is secreted normally in an nce2-1 mutant, the Nce2p transporter is apparently not required for AFRP export (Nijbroek and Michaelis, unpublished data) . Finally, it is theoretically possible that AFRP could exit the cell via simple diffusion. However, we feel that this is not likely in light of the finding that the export kinetics of AFRP and a-factor are strikingly similar ( Figure 2) ; such similar kinetics of export would be unlikely if one molecule were exiting by diffusion and the other were undergoing active transport. Furthermore, there is increasing evidence that even small lipophilic molecules such as steroids, which were once thought to cross lipid bilayers unaided, can be assisted across membranes by transporters. This is exemplified by the efflux of steroid molecules such as dexamethasone from yeast by the Pdr5p transporter (Kralli et al., 1995) . It will, of course, be an interesting challenge to identify the AFRP transporter. However, because we do not presently have a simple assayable phenotype to follow, identification of such a component at this time would require brute force screening of candidate mutants using metabolic labeling followed by SDS-PAGE.
Specificity of the Protease that Generates AFRP Prenylation appears to be a critical modification for the production of both a-factor and AFRP. We have previously shown that during the biogenesis of a-factor, Cterminal prenylation of the precursor is required for its membrane association and for subsequent N-terminal proteolytic processing to form mature a-factor (Chen et al., 1997 ). Herein we demonstrate that prenylation is also a prerequisite for the formation of AFRP; since mfal-CAAX mutants (AVIA, Al), or cellular prenylation-defective mutants (raml, ram2), are unable to generate AFRP. One potential explanation for this prenyl requirement is that the AFRP protease (itself possibly membrane-associated, like the a-factor protease Ste24p) can encounter the precursor only when it is membrane-associated. Alternatively, or in addition, the prenyl group could serve as a specific recognition determinant or landmark for the AFRP protease.
One feature that the AFRP cleavage sites have in common in WT MFA1 and in the fusion constructs is that they are close (9 amino acids or fewer) to the prenylated cysteine. Our fusion constructs contain an intact CAAX motif but have foreign amino acids adjacent to CAAX, instead of authentic a-factor residues. Unexpectedly, strains expressing these fusions secrete molecules of approximately the same size as AFRP whose amino acid composition corresponds to the newly introduced residues, instead of the authentic a-factor residues ( Figures  11 and 12) . Thus, an attractive possibility is that the AFRP protease recognizes prenylcysteine as a landmark and cleaves the substrate a relatively fixed distance away from it, independent of the sequence at the cleavage site. Alternatively, because it is likely that prenylcysteine serves as an anchor point in the membrane for a-factor, the AFRP protease could measure a particular distance from the membrane per se and cleave its substrate at that point. Indeed, one such proteolytic activity has been described that cleaves (3-amyloid at a fixed distance from its membrane span, regardless of the amino acid residues that are present at the cleavage site (Sisodia, 1992) .
In the analysis of AFRP derived from WT MFA1 and from our fusion constructs, we observe sequence-independent cleavage, with cleavage occurring between unrelated pairs of amino acids: Gly-Val for AFRP, Leu-Tyr for fusion 1, and Tyr-Asp for fusion 2 (and perhaps other amino acid pairs if the smaller species we detect in Figure 12 are indeed generated intracellularly). Clearly, such a diverse processing pattern could not be achieved by a protease whose recognition sequence is highly specific. One candidate protease that could accomplish cleavage at multiple sites is the proteosome, since it is known to have multiple endopeptidase activities (Hochstrasser et al., 1991; Hochstrasser, 1995) . However, in a mutant defective for protease function (prel-1), the production of AFRP is unaffected, indicating that the proteosome is not the AFRP protease (Choi and Michaelis, unpublished observation). We note that although we cannot rule out the possibility that cleavage of the fusion proteins is occurring by a different protease than the authentic AFRP-producing protease, there is no compelling reason to invoke two separate proteolytic activities. In contrast to the AFRP protease, the a-factor proteases, Ste24p and Axllp, show a high degree of substrate specificity, because mutations in residues flanking their cleavage sites can block processing (Fujimura-Kamada et al., 1997; Nouvet, Kistler, and Michaelis, unpublished results). Yet for these proteases too, the distance of the cleavage site from prenyl cysteine may also be important, because cleavage by these proteases is significantly blocked by insertions that alter the distance between the prenyl cysteine of a-factor and the Ste24p or Axllp cut sites (Nouvet and Michaelis, unpublished observations). Another C-terminally cleaved CAAX protein, mammalian nuclear lamin A, is initially C-terminally prenylated and methylated (Weber et al., 1989) . However, as part of its normal life cycle, its C terminus, including the prenylated methylated cysteine, is cleaved off. The lamin A protease is specific, like the a-factor proteases, because mutations flanking its cut site block its use (Hennekes and Nigg, 1994 ). An interesting model is that prenylcysteine serves as a recognition landmark for all proteases that act upon CAAX substrates. The AFRP protease, however, may be distinctive among these by virtue of its ability to cleave at many different residues.
In light of its lack of substrate specificity, it is reasonable to ask whether the AFRP protease could have a general cellular role for the cleavage of prenyl proteins unrelated to a-factor and AFRP, for instance acting upon Ras or the G protein y subunit, which represent two important signaling molecules (Clarke, 1992) . Cleavage by such a protease could serve a down-regulatory function by permanently inactivating these proteins. Alternatively, the AFRP protease may play an important general catabolic function. It is interesting to note that no cellular mechanism is presently known for the metabolic turnover of prenyl groups (Zhang and Casey, 1996) ; the thioether bond between the sulfur of cysteine and the farnesyl carbon is an extremely stable bond. Because prenylcysteine can neither be broken down for recycling nor be reused as is, to be cleared, it may instead need to be discarded from the cell. The AFRP protease in conjunction with the putative AFRP transporter could provide a way for cells to accomplish this task.
Kinetically, the formation of mature a-factor versus AFRP are similar, as determined by pulse-chase experiments. Operationally, there appear to be two different pools of P1 in the cell, one acted upon by the a-factor protease Ste24p and the other by the AFRP protease. Whether the content of these pools is determined stochastically or as the result of a particular conformation or location of a portion of the P1 precursor is not clear.
What Is the Physiological Role of AFRP? Although the amount of AFRP that is exported from the cell is comparable to that of a-factor, the physiological role of AFRP is not known. Unlike a-factor, AFRP does not appear to possess either a significant stimulatory activity or an inhibitory activity: We detected nearly no activity by the halo assay, in which serial dilutions of AFRP are tested for their ability to mediate the growth arrest of MATa cells. Similarly, when we tested whether AFRP has an inhibitory role in mating, perhaps acting as an antagonist for the a-factor receptor, we did not detect an inhibition of mating resulting from the addition of exogenous AFRP to mating cells. These results are consistent with those of Becker and coworkers (Caldwell et al., 1994) , who examined the activity of chemically synthesized Vol. 8, July 1997 versions of a-factor that were N-terminally truncated. One of the compounds tested by this group had precisely the composition of AFRP, except that it was presumably unoxidized. This compound exhibited a dramatically reduced activity when compared with a-factor (4000-fold reduced for growth arrest, and 125-fold reduced for mating restoration). Nevertheless it is interesting that in these studies it was possible to detect a low residual activity associated with synthetic AFRP. Presumably, with sufficiently high chemical quantities of this material, it is possible to reach a detection threshold where a very low level of activity can be observed. The AFRP that we purified appears to be oxidized, which may also lessen its activity. We do not know whether this oxidation occurs in vivo or whether it reflects an artifact of preparation. Indeed oxidation of mature a-factor has been seen in previous a-factor purification studies (Betz et al., 1987) , although its affect on mating has not been determined.
It remains possible that AFRP may have a role in mating. It is now known that high levels of pheromones are produced, indeed required, during the late stages in mating, in particular for cell fusion (Brizzio et al., 1996) . We have examined a-factor and AFRP production during the late stages of mating and indeed found that AFRP is produced at levels similar to that of a-factor (Choi and Michaelis, unpublished observations) . However, it is presently difficult to assess the specific role of AFRP, as its production is inseparable from that of a-factor. This issue will only be approachable when we can generate mutants that are defective for AFRP protease or the AFRP exporter.
Detection of AFRP Our ability to detect AFRP has always been somewhat variable. There are two factors that might contribute to this variability. First, the particular antiserum preparation used for the immunoprecipitations appears to be critical; antiserum from later bleedings appear to recognize AFRP better than antiserum from the earlier bleedings. No obvious difference has been observed for the recognition of other a-factor species. Second, the separation of M and AFRP is extremely sensitive to subtle alterations in electrophoresis conditions; often several independent gel runs are required to achieve sufficient resolution of a-factor and AFRP.
Another issue that complicated our analysis is that AFRP, although it can be immunoprecipitated efficiently from the intracellular fraction, is not efficiently immunoprecipitated from the extracellular fraction (unless a-factor is absent). One possible explanation for this phenomenon is that the extra 16 Da on AFRP, presumably representing oxidation, may partially obscure the epitope recognized by our antiserum. It is possible that this modification may occur only after AFRP is secreted, which could account for the distinctly different immunoprecipitability of the differently located AFRP molecules. A second possibility we have considered is somewhat more complex, but intriguing. It is based on the analysis of the intracellular fraction of cells expressing fusion constructs; we have observed that we can use a-factor antibodies to immunoprecipitate intracellular AFRP-sized molecules that contain foreign residues in place of the normal a-factor residues (Chen, 1993) . Presumably these species are precipitated indirectly, by virtue of their noncovalent and SDS-resistant association with precursors containing a-factor sequences. Therefore, it is possible that intracellular AFRP is also associated with such an SDS-resistant complex in the cell. Were such a structure to exist only inside of cells, then extracellular AFRP would have no way to be efficiently pulled down by our antiserum. More experiments are needed to clarify this potentially interesting point.
It is remarkable that the a-factor precursor, which is one of the smallest known peptides in the cell, has so much cellular machinery dedicated to its modification, processing, and export. With the analysis of AFRP described herein, we provide further evidence that the biogenesis of the a-factor mating pheromone is even more complicated, but certainly more interesting, than we originally thought because the precursor participates in not one but two maturation pathways each with distinctive proteolytic and export machinery.
